- Type of Event: Q2 and H1 FY27 Earnings Conference Call to discuss financial and operational performance/Unaudited Financial Results (Standalone and Consolidated).
- Date and Time: The call was held on Friday, November 13, 2026. A specific time and time zone were not mentioned in the transcript.
- Purpose: To discuss the company's performance for the quarter and half year ended September 30, 2026.
- Earnings Announcement Timing: The meeting was held after the earnings announcement, as it was a discussion of the results.
- Management Participants: Mr. Aryan Sehgal (Promoter and Whole-Time Director) and Mr. Santosh Agarwal (Chief Financial Officer). An IR partner from SGA was also mentioned.
- Presentation Availability: An investor presentation was uploaded on the company's website and stock exchanges prior to the call. The transcript of the call was also uploaded to the company's website at www.tarsons.com.
- UPSI Statement: The moderator's opening remarks contained a standard forward-looking statement disclaimer, noting that the call may contain forward-looking statements that are not guarantees of future performance. The company did not include a specific statement indicating that no Unpublished Price Sensitive Information (UPSI) would be shared.
Financial Highlights & Strategic Themes (as disclosed in the call):
- The financial period discussed was Q2 and H1 FY27 (ended September 30, 2026).
- Standalone Performance: Q2 revenue grew 25% YoY to over INR 100 crores (a first for the company). H1 revenue grew 23% YoY. Domestic revenue grew 19% in Q2, while export revenue grew 37%.
- Consolidated Performance: H1 FY27 consolidated revenue was INR 233.9 crores, up 21% YoY.
- Margins: Gross profit stood at INR 67.4 crores in Q2 (up 15% YoY), with gross margins moderating primarily due to a 30-50% increase in crude-linked raw material prices since the West Asia conflict began in March 2026. Standalone EBITDA for Q2 was INR 30.6 crores (up 16.9% YoY).
- Subsidiary (Nerbe): Revenue increased by 7% in Q2 FY27 and 13% in H1 FY27 on a YoY basis. Margins were subdued due to new hiring and inflation.
- Cash Flow: Standalone operating cash flow improved from INR 40 crores in H1 FY26 to INR 49 crores in H1 FY27.
- Capacity Expansion: The company is in the final phase of a major expansion, commissioning new facilities in Panchla and Amta. The cell culture lines at Panchla are expected to be commissioned in the second half of the year. The total revenue potential from old and new facilities is estimated at INR 800 crores on a standalone basis.
- Guidance & Outlook: Management expressed confidence in sustaining growth momentum due to an uptick in inquiries and improved demand, especially in pharma and healthcare. They expect benefits from new capacities to become increasingly visible from FY28 onwards, driving revenue growth and operating leverage. Near-term PAT is impacted by accelerated depreciation and interest costs from new facilities.
- Challenges: Significant pressure from high raw material costs and global container availability issues affecting export shipments.
Additional Notes Section
- The document is an intimation letter to the stock exchanges (BSE and NSE) enclosing the transcript of the earnings call, which was held on November 13, 2026.
- The transcript was edited for factual errors, with the audio recording from November 13, 2026, taking precedence in case of discrepancy.
- The transcript contained a detailed Q&A session with analysts covering topics such as margin outlook, export sustainability, competition, capacity commissioning delays, and working capital management.
- No new financial data was disclosed in this specific announcement/intimation letter itself; it served to provide the transcript of the call where financials were discussed.